Biotech's New Company Model: Chinese Assets and the IND-Bridging Problem

A Different Way to Start a Biotech

Endpoints News this week described a startup model that has been forming quietly since 2025: small US biotech teams launching with one or two clinical-stage assets in-licensed from China, large initial financings, and a focused commercial strategy built around the in-licensed pipeline. Endpoints identified at least 18 private biotechs that have followed this route since the beginning of 2025.

The model is a meaningful departure from how US biotechs have historically been built. Most US biotechs started with a piece of fundamental science and worked for years to build a drug around it. The new model skips the early discovery years entirely: the asset is already in clinical development by the time the US company is incorporated.

For investors, the model offers faster paths to value inflection. For the regulatory writing function, it offers a particular kind of documentation problem that the industry has been navigating for years but that this surge in NewCo activity is making much more visible.

The Bridging Problem

When a clinical-stage asset moves from a Chinese sponsor to a US biotech via licensing, the asset's regulatory dossier moves with it. The Chinese sponsor will typically have completed Phase 1 and possibly Phase 2 studies under Chinese regulatory authorities. The clinical study reports, the investigator brochure, the trial documentation, and the manufacturing dossier all exist — in Mandarin, in Chinese regulatory format, and to Chinese standards.

The US biotech, having taken the rights, now needs to convert this dossier into a form that the FDA will accept. The conversion is not a translation problem. It is a regulatory-framework problem layered on top of a translation problem.

The Chinese clinical trial documentation will have been produced to NMPA standards. Trial design assumptions, statistical analysis plans, adverse event reporting frameworks, and case report form definitions all have NMPA-shaped conventions. The Investigator's Brochure structure follows Chinese norms. The manufacturing dossier reflects Chinese GMP expectations.

To file an IND in the United States — or to convince the FDA that the Chinese data can support a Phase 2b or Phase 3 in the US — the writing function has to produce a bridging package that meets FDA expectations while honouring the data and conclusions of the original studies.

What the Bridging Package Actually Has to Do

Three core writing tasks define a competent bridging package.

Reconcile the trial design to FDA expectations. A Chinese Phase 2 study, designed in 2023, may have used endpoint definitions, control arm choices, or statistical thresholds that differ from what the FDA would have accepted for the same design. The bridging documentation needs to explain those choices, defend them where they are defensible, and identify where additional data or analyses are needed to satisfy the FDA's expectations. This work is mostly narrative — the data is what it is, the bridging is in how the data is framed.

Translate the manufacturing dossier. Chinese GMP and US cGMP are convergent but not identical. The CMC sections of the IND need to describe the manufacturing process in a way that addresses FDA-specific concerns: where the analytical methods are validated, how the supply chain is audited, what comparability assessments have been done if the manufacturing site has changed since the original trials. For biologics in particular, the comparability narrative is where most bridging packages spend the most writing effort.

Restructure the safety narrative. Adverse event coding may have used MedDRA versions or hierarchies that differ from current FDA expectations. Serious adverse event handling and timelines may have been managed under different reporting frameworks. The bridging documentation needs to present the safety data in a structure that the FDA can review on its own terms, without losing fidelity to the original observations.

Each of these is non-trivial writing work. The aggregate package, for a typical clinical-stage in-license, runs to hundreds of pages of carefully constructed narrative and several thousand pages of supporting data. The work takes a regulatory writing team that knows both regulatory frameworks deeply, plus a translation function that understands clinical and statistical nuance, plus a project manager who can keep the bridging timeline aligned with the US biotech's IPO or financing milestones.

Why This Is Suddenly More Visible

The NewCo trend that Endpoints describes is not the first time Chinese assets have been brought to the US under license. What is new is the scale and pace.

Eighteen US biotechs in fifteen months means roughly one new NewCo per month. Each one has an in-license to bridge. Each one is small enough that the regulatory writing function is typically two to five people, often heavily contractor-supported. None of them has the institutional depth that, say, a large pharma's in-licensing function brings to the same problem.

The aggregate effect is a sudden surge in bridging-package demand at a quality level that most contract writing firms have not previously been asked to deliver at scale. The good firms are oversubscribed. The mediocre firms are producing bridging packages that the FDA is finding insufficient.

The companies that succeed in this model will be the ones who treat the bridging package as a strategic asset, not a procedural step. The packages that win the regulatory case for the in-licensed asset are the ones that translate the Chinese data into an FDA-readable case, anticipate the agency's questions, and address them in the original submission rather than waiting for Information Requests.

What Newco Founders Should Know

For founders of biotechs built on this model, three practical considerations are worth thinking through before the regulatory work starts.

The bridging package is the first major writing deliverable, and the timeline is on the financing clock. If the company raised a Series A in March with an IPO targeted for late 2027, the IND has to be in by Q4 2026 for the timing to work. That means the bridging package needs to be drafted, reviewed, and ready by Q3 2026. Writing teams need to be sized against that calendar from day one.

The translation work is not interchangeable with the bridging work. Both are required. Neither substitutes for the other. Companies that try to do bridging by handing translated documents to a US writing team without adequate framework-translation context produce bridging packages that read as awkwardly Sinicised English rather than as competently constructed FDA submissions.

The agency is reading more bridging packages than it used to. The FDA is, by all available signals, getting more sophisticated about reading bridging packages and faster at identifying the patterns that distinguish a competently bridged dossier from a poorly bridged one. The bar is rising. Sponsors that approach the bridging as a procedural step will be reviewed against a standard that assumes strategic effort.

The new biotech model is interesting. The regulatory writing problem underneath it is not new. What is new is how much of the new regulatory writing work is now bridging work — and how few writing teams are explicitly resourced to do it well.